HeartFlow Introduces Next Generation Platform
REDWOOD CITY, Calif. – June 23, 2016 – HeartFlow, Inc., a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated, announced today that it is launching its next generation of the HeartFlow® FFRCT Analysis. The result of years of development, the next generation platform includes major advancements in the process and algorithms […]
Technology from HeartFlow Provides Insights to Help Identify Coronary Plaques at Risk of Rupturing
Hemodynamic Assessment Could Improve Prediction of Acute Coronary Syndrome Risk PARIS – May 19, 2016 – First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow, Inc., may help predict which coronary plaques have the potential to rupture. The results were part of a study esigned to determine whether use of HeartFlow technology could […]
Highmark Health’s VITAL program partners with Allegheny Health Network and HeartFlow to evaluate a novel 3D technology
New modeling tool aids physicians’ ability to identify best treatment for patients with coronary artery disease Pittsburgh PA and Redwood City, CA (April 25, 2016) – Highmark Health, Allegheny Health Network (AHN), and HeartFlow, Inc. announced today that they are partnering to evaluate a novel non-invasive diagnostic technology that offers physicians insight into both the extent […]
One-Year PLATFORM Trial Results Reinforce Benefits of the HeartFlow FFRCT Analysis for Assessing Coronary Artery Disease
A HeartFlow FFRCT-Guided Strategy Helps Physicians Avoid Unnecessary Invasive Coronary Diagnostics CHICAGO, Ill. – April 4, 2016 – Novel technology developed by HeartFlow, Inc. significantly reduces the need for invasive procedures to diagnose patients suspected of having coronary artery disease. The HeartFlow® FFRCT Analysis also leads to a sustained reduction in the cost of care, according to one-year data […]
Trial Demonstrates HeartFlow FFRCT Analysis Significantly Lowers Cost of Care, Improves Quality of Life for Coronary Artery Disease
Up to 32% reduction in cost when using FFRCT-guided treatment strategy compared to invasive coronary angiography SAN FRANCISCO – Oct. 13, 2015 – New data shows that technology developed by HeartFlow, Inc. could lower the cost of evaluating patients with suspected coronary artery disease by as much as 32 percent. The late-breaking data, presented at the annual Transcatheter […]
HeartFlow Secures 50th U.S. Patent
Patents Issued to Date Provide Broader Protection for Company’s FFRCT Technology REDWOOD CITY, Calif. – Oct. 7, 2015 – HeartFlow Inc., a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated, today announced that the United States Patent and Trademark Office has issued to HeartFlow its 50th patent. The patent, “Method and System […]
PLATFORM Trial Shows HeartFlow FFRCT Analysis Significantly Decreases Unnecessary Invasive Diagnostic Testing for Coronary Artery Disease
83% reduction in invasive tests showing no obstructive disease; revascularization rates unchanged LONDON – Sept. 1, 2015 – A technology developed by HeartFlow, Inc. has been shown to significantly reduce the use of invasive catheterization in patients with suspected coronary artery disease, according to a study presented today in a “Hot Line” session at the European Society of […]
HeartFlow Names New General Counsel to Executive Team
REDWOOD CITY, Calif. – Dec. 23, 2014 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, has appointed Noemi C. (“Nicky”) Espinosa, as general counsel. Espinosa brings to HeartFlow 30 years of experience as both a business executive and outside counsel, representing medical device, life science and high tech companies. “Nicky’s extensive experience and […]
HeartFlow Appoints Former Johnson & Johnson Chairman and CEO William C. Weldon to Board of Directors
REDWOOD CITY, Calif. – Dec. 10, 2014 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, has named William C. Weldon a new member of its board of directors. Weldon, who previously served as chairman and CEO of global healthcare products company Johnson & Johnson, joins the company’s board following the U.S. Food and […]
HeartFlow Secures De Novo Clearance from the U.S. Food and Drug Administration for Breakthrough FFRCT Technology
Highly Accurate, Non-invasive Test Has the Potential to Change the Way Coronary Artery Disease is Managed REDWOOD CITY, Calif. – Dec. 1, 2014 – HeartFlow Inc., a pioneer in personalized medical technology for cardiovascular disease, today announced that it received de novo clearance from the U.S. Food and Drug Administration for its FFRCT technology. HeartFlow FFRCT is the first […]
